Immuneering Corp (IMRX) stock
IMRXNasdaqPharmaceutical PreparationsFiscal year ends December 31
$3.71+0.04 (+1.09%)
Close on Nov 13, 2026Market cap $240.27MP/E –Yield –
Immuneering ebitda
EBITDA is earnings before interest, taxes, depreciation and amortization, a rough measure of cash profit from operations.
Immuneering's ebitda for the twelve months ending Sep 30, 2026 was -$73.55M. For fiscal 2025 it was -$59.05M.
Annual ebitda
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$59.05M | – |
| FY2024 | Dec 31, 2024 | -$63.72M | – |
| FY2023 | Dec 31, 2023 | -$58.09M | – |
Quarterly ebitda
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | -$25.70M | – |
| Q2 FY2026 | Jun 30, 2026 | -$18.92M | – |
| Q1 FY2026 | Mar 31, 2026 | -$15.25M | – |
| Q4 FY2025 | Dec 31, 2025 | -$13.68M | – |
| Q3 FY2025 | Sep 30, 2025 | -$15.30M | – |
| Q2 FY2025 | Jun 30, 2025 | -$14.67M | – |
| Q1 FY2025 | Mar 31, 2025 | -$15.40M | – |
| Q4 FY2024 | Dec 31, 2024 | -$18.47M | – |
| Q3 FY2024 | Sep 30, 2024 | -$15.18M | – |
| Q2 FY2024 | Jun 30, 2024 | -$14.82M | – |
| Q1 FY2024 | Mar 31, 2024 | -$15.24M | – |
| Q4 FY2023 | Dec 31, 2023 | -$16.21M | – |
| Q3 FY2023 | Sep 30, 2023 | -$13.85M | – |
| Q2 FY2023 | Jun 30, 2023 | -$13.43M | – |
| Q1 FY2023 | Mar 31, 2023 | -$14.60M | – |
| Q3 FY2022 | Sep 30, 2022 | -$13.12M | – |
| Q2 FY2022 | Jun 30, 2022 | -$11.59M | – |
See a number that looks wrong?